Infinity To Present At Several Upcoming Conferences

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the following upcoming conferences:
  • Rodman & Renshaw Annual Global Investment Conference – New York City, September 10, 2012, at 4:55 p.m. ET
  • Morgan Stanley Global Healthcare Conference – New York City, September 11, 2012, at 1:00 p.m. ET
  • ThinkEquity 9 th Annual Growth Conference – New York City, September 12, 2012, at 8:45 a.m. ET
  • UBS Global Life Sciences Conference – New York City, September 20, 2012, at 10:30 a.m. ET

A live webcast of each of Infinity's presentations will be accessible on the Investors/Media section of the company's website, www.infi.com, and will be available for 30 days following each event.

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative drug discovery and development company seeking to discover, develop and deliver to patients best-in-class medicines for diseases with significant unmet need. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity’s programs focused on the inhibition of phosphoinositide-3-kinase, heat shock protein 90 and fatty acid amide hydrolase are evidence of its innovative approach to drug discovery and development. For more information on Infinity, please refer to the company’s website at www.infi.com.

Copyright Business Wire 2010

If you liked this article you might like

This Market Action Is Not Creating Many Setups

This Market Action Is Not Creating Many Setups

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results

Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

7 Stocks Under $10 to Trade for Big Post-Brexit Gains